Danemark -
danois -
Lægemiddelstyrelsen (Danish Medicines Agency)
rocuronium "hameln" 10 mg/ml injektions-/infusionsvæske, opløsning
hameln pharma gmbh - rocuroniumbromid - injektions-/infusionsvæske, opløsning - 10 mg/ml
Danemark -
danois -
Lægemiddelstyrelsen (Danish Medicines Agency)
rocuronium "fresenius kabi" 10 mg/ml injektions-/infusionsvæske, opløsning
fresenius kabi ab - rocuroniumbromid - injektions-/infusionsvæske, opløsning - 10 mg/ml
Danemark -
danois -
Lægemiddelstyrelsen (Danish Medicines Agency)
rocuronium bromide "aguettant" 10 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte
laboratoire aguettant - rocuroniumbromid - injektionsvæske, opløsning i fyldt injektionssprøjte - 10 mg/ml
Danemark -
danois -
Lægemiddelstyrelsen (Danish Medicines Agency)
esmeron 10 mg/ml injektionsvæske, opløsning
merck sharp & dohme b.v. - rocuroniumbromid - injektionsvæske, opløsning - 10 mg/ml
Union européenne -
danois -
EMA (European Medicines Agency)
bridion
merck sharp & dohme b.v. - sugammadex - neuromuskulær blokade - alle andre terapeutiske produkter - tilbagevendelse af neuromuskulær blokade induceret af rocuronium eller vecuronium. for peadiatric befolkning: sugammadex er kun anbefales til rutinemæssig tilbageførsel af rocuronium-induceret blokade i børn og unge.
Union européenne -
danois -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Union européenne -
danois -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Union européenne -
danois -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - tilbagevendelse af neuromuskulær blokade induceret af rocuronium eller vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Union européenne -
danois -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulær blokade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
Union européenne -
danois -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulær blokade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.